IL-2 and IL-4 double knock-out mice reject islet allografts: a role for novel T-cell growth factors?
Roy-Chaudhury
P
P
Division of Immunology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Manfro
R C
RC
Steiger
J
J
Nickerson
P W
PW
Tian
Y
Y
Zheng
X X
XX
Li
Y S
YS
Strom
T B
TB
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D017252:CD3 Complex / Q000276:immunology; D003921:Diabetes Mellitus, Experimental / Q000601:surgery; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology; D006085:Graft Survival; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007376:Interleukin-2 / Q000235:genetics / Q000276:immunology*; D015847:Interleukin-4 / Q000235:genetics / Q000276:immunology*; D016381:Islets of Langerhans Transplantation / Q000276:immunology* / Q000473:pathology; D008213:Lymphocyte Activation; D051379:Mice; D008811:Mice, Inbred DBA; D018345:Mice, Knockout; D011090:Polyenes / Q000627:therapeutic use; D020123:Sirolimus; D013154:Spleen / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous
D000906:Antibodies; D017252:CD3 Complex; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D011090:Polyenes; D015847:Interleukin-4; D020123:Sirolimus